Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals.
作者信息
Batista-Duharte Alexander, Aliño Salvador F
机构信息
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Cordoba, Spain.
Farmacogenetics and Gene Therapy Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
出版信息
Front Allergy. 2023 May 24;4:1214914. doi: 10.3389/falgy.2023.1214914. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals.社论：生物制药的免疫相关不良事件（irAEs）
Front Allergy. 2023 May 24;4:1214914. doi: 10.3389/falgy.2023.1214914. eCollection 2023.
2
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.抗程序性死亡-1药物治疗后不良事件的管理
Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8.
3
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.免疫相关不良反应预测抗 PD-1 抗体在癌症患者中的治疗效果。
Eur J Cancer. 2019 Mar;109:21-27. doi: 10.1016/j.ejca.2018.10.014. Epub 2019 Jan 22.
4
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?免疫检查点抑制剂相关的血液学免疫不良反应，如何管理？
Eur J Cancer. 2019 Nov;122:72-90. doi: 10.1016/j.ejca.2019.07.014. Epub 2019 Oct 18.
5
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.抗PD-1或抗PD-L1免疫疗法诱导的血液学免疫相关不良事件：一项描述性观察研究。
Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.
6
Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.免疫检查点抑制剂治疗在各种实体瘤的日本患者中的免疫相关不良反应和抗肿瘤疗效的流行率。
BMC Cancer. 2022 Nov 29;22(1):1232. doi: 10.1186/s12885-022-10327-7.
7
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.抗 PD-1 抗体治疗的各种癌症患者的免疫相关不良事件与预后的相关性。
BMC Cancer. 2020 Jul 14;20(1):656. doi: 10.1186/s12885-020-07142-3.
8
Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.帕博利珠单抗和化疗治疗非小细胞肺癌患者的疗效与免疫相关不良事件的相关性：一项回顾性研究。
BMC Cancer. 2022 Oct 6;22(1):1047. doi: 10.1186/s12885-022-10133-1.
9
Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.基于临床和血液学指标预测接受免疫检查点抑制剂治疗的非小细胞肺癌患者的免疫相关不良事件：真实世界证据
Exp Cell Res. 2022 Jul 1;416(1):113157. doi: 10.1016/j.yexcr.2022.113157. Epub 2022 Apr 12.
10
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.免疫相关不良事件与晚期非小细胞肺癌疗效的关联：系统评价和荟萃分析。
Immunotherapy. 2023 Feb;15(3):209-220. doi: 10.2217/imt-2022-0028. Epub 2023 Jan 30.
本文引用的文献
1
Biopharmaceutical benchmarks 2022.2022 年生物制药基准报告
Nat Biotechnol. 2022 Dec;40(12):1722-1760. doi: 10.1038/s41587-022-01582-x.
2
Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches.用于疫苗改进的免疫检查点抑制剂：现状与新方法
Pharmaceutics. 2022 Aug 17;14(8):1721. doi: 10.3390/pharmaceutics14081721.
3
Immune Checkpoint Inhibitors in Cancer Therapy.癌症治疗中的免疫检查点抑制剂。
Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247.
4
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
5
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.免疫检查点抑制剂免疫相关不良事件的临床特征与治疗
Immune Netw. 2020 Feb 17;20(1):e9. doi: 10.4110/in.2020.20.e9. eCollection 2020 Feb.
Zotero 插件